CLINICAL TRIALS PROFILE FOR LARODOPA
✉ Email this page to a colleague
All Clinical Trials for LARODOPA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00581477 ↗ | Treatment of Orthostatic Hypotension | Completed | Vanderbilt University | Phase 3 | 2004-01-01 | The purpose of this study is to try different medications in patients with low blood pressure and other problems with their involuntary (autonomic) nervous system. The pharmacological trials in this study will perhaps lead to more effective treatment. This study consists of single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months) trials. |
| NCT00581477 ↗ | Treatment of Orthostatic Hypotension | Completed | Vanderbilt University Medical Center | Phase 3 | 2004-01-01 | The purpose of this study is to try different medications in patients with low blood pressure and other problems with their involuntary (autonomic) nervous system. The pharmacological trials in this study will perhaps lead to more effective treatment. This study consists of single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months) trials. |
| NCT02560389 ↗ | Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) | Completed | University of Arkansas | Phase 4 | 2016-03-01 | The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities. |
| NCT02560389 ↗ | Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) | Completed | University of Wisconsin, Madison | Phase 4 | 2016-03-01 | The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LARODOPA
Condition Name
Clinical Trial Locations for LARODOPA
Trials by Country
Clinical Trial Progress for LARODOPA
Clinical Trial Phase
Clinical Trial Sponsors for LARODOPA
Sponsor Name
